Article
Oncology
Alexandra Diggs, Tiffany Y. Sia, Yongmei Huang, Allison Gockley, Alexander Melamed, Fady Khoury-Collado, Caryn St. Clair, June Y. Hou, Dawn L. Hershman, Jason D. Wright
Summary: This study analyzed the utilization of adjuvant chemotherapy and radiation therapy in patients with stage II and III uterine leiomyosarcoma (uLMS). The results showed that the use of chemotherapy is increasing while the use of radiation therapy is decreasing. Radiation therapy is associated with improved survival in both stage II and III disease, but there is no association between adjuvant chemotherapy and survival in stage II patients.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Ravi Shridhar, Paige Blinn, Jamie Huston, Kenneth L. Meredith
Summary: This study is the first to show that adjuvant radiation therapy after chemotherapy can significantly improve overall survival in resected high-risk extrahepatic cholangiocarcinoma patients. Further clinical trials are needed to investigate the role of radiation therapy in this population.
Article
Oncology
Seo Hee Choi, Chai Hong Rim, In-Soo Shin, Won Sup Yoon, Woong Sub Koom, Jinsil Seong
Summary: The study shows that adjuvant radiotherapy can improve overall survival in patients with extrahepatic cholangiocarcinoma, and further confirm this result in studies with reliable comparability.
Article
Oncology
Jung Ho Im, Gi Hong Choi, Woo Jung Lee, Dai Hoon Han, Seung Woo Park, Seungmin Bang, Hye Jin Choi, Jinsil Seong
Summary: The study suggests that adjuvant chemoradiotherapy may benefit patients with perihilar cholangiocarcinoma. For R1 resection patients and stage III-IVA patients, adjuvant chemotherapy or chemoradiotherapy is recommended for improved overall survival. Further prospective studies are needed to validate these findings.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Review
Medicine, General & Internal
Sudha Kodali, Akshay Shetty, Soumya Shekhar, David W. Victor, Rafik M. Ghobrial
Summary: Cholangiocarcinoma, a tumor arising from differentiation of cholangiocytes, can develop anywhere in the biliary tree. Early diagnosis allows for surgical resection, while late-stage intrahepatic cholangiocarcinoma cases may require chemotherapy, locoregional therapies, and radiation as treatment options.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Rogier Baak, Francois E. J. A. Willemssen, Yvette van Norden, Ferry A. L. M. Eskens, Maaike T. W. Milder, Ben J. M. Heijmen, Bas Groot Koerkamp, Dave Sprengers, Lydi M. J. W. van Driel, Heinz-Josef Klumpen, Wilhelm den Toom, Merel S. Koedijk, Jan N. M. IJzermans, Alejandra Mendez Romero
Summary: This study examined the feasibility and safety of adding SBRT treatment in patients with unresectable perihilar cholangiocarcinoma, showing promising results in terms of local control and overall survival. However, further evaluation in a larger patient population is recommended due to the small sample size in this study.
Article
Oncology
Alix Dhote, Stylianos Tzedakis, Christian Hobeika, Ugo Marchese, Romain Coriat, Alexandra Nassar, Adrelie Beaufrere, Tatiana Codjia, Claire Goumard, Olivier Scatton, Anthony Dohan, Maxime Ronot, Benoit Terris, Mickael Lesurtel, Safi Dokmak, Francois Cauchy, David Fuks
Summary: This study analyzed the oncological outcomes of ICC patients who underwent radical surgery after preoperative treatment. The study found that patients with initially unresectable ICC who underwent preoperative treatment followed by curative-intent resection had similar long-term outcomes as those undergoing upfront surgery.
Review
Gastroenterology & Hepatology
Xing Chen, Jinpeng Du, Jiwei Huang, Yong Zeng, Kefei Yuan
Summary: Intrahepatic cholangiocarcinoma (ICC) is a common type of primary liver cancer with increasing incidence. Due to the lack of specific manifestations and tools for early diagnosis, most patients are diagnosed at an advanced stage. Neoadjuvant and adjuvant therapies are necessary to improve the outcomes, but lag behind compared to other malignancies. Recent advances in neoadjuvant and adjuvant strategies for ICC are evaluated in this review.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
(2022)
Article
Oncology
Xiao-hui Li, En-liang Zhou, Chong-yu Zhao, Bo-kang Cui, Xiao-yuan Dong, Hang Du, Xiao-jun Lin
Summary: Combining postoperative adjuvant chemotherapy with immunotherapy extends the relapse-free survival (RFS) and overall survival (OS) of patients with cholangiocarcinoma following radical resection.
Article
Oncology
Takefumi Komiya, Shinkichi Takamori, Gregory Wilding
Summary: This study suggests that adjuvant radiation may still play a role in improving overall survival in patients with persistent N2 disease after neoadjuvant chemotherapy. Adjuvant radiation may have a beneficial effect in patients who are not downstaged to pN0-1.
RADIOTHERAPY AND ONCOLOGY
(2022)
Article
Gastroenterology & Hepatology
Yutaka Endo, Zorays Moazzam, Laura Alaimo, Henrique A. Lima, Muhammad M. Munir, Chanza F. Shaikh, Alfredo Guglielmi, Luca Aldrighetti, Matthew Weiss, Todd W. Bauer, Sorin Alexandrescu, George A. Poultsides, Minoru Kitago, Shishir K. Maithel, Hugo P. Marques, Guillaume Martel, Carlo Pulitano, Feng Shen, Francois Cauchy, Bas G. Koerkamp, Itaru Endo, Timothy M. Pawlik
Summary: The study developed a predictive model based on tumor characteristics to help identify which patients may benefit the most from adjuvant chemotherapy after resection of ICC. Results showed that patients receiving AC had a survival benefit in high/medium-risk categories but not in low-risk category.
Article
Oncology
Wenjie Ni, Shufei Yu, Zefen Xiao, Zongmei Zhou, Dongfu Chen, Qinfu Feng, Jun Liang, Jima Lv, Shugeng Gao, Yousheng Mao, Qi Xue, Kelin Sun, Xiangyang Liu, Dekang Fang, Jian Li, Dali Wang, Jun Zhao, Yushun Gao
Summary: The study demonstrated that postoperative radiotherapy/postoperative concurrent chemoradiotherapy (PORT/POCRT) could significantly improve disease-free survival and overall survival in patients with stage IIB-III esophageal squamous cell carcinoma.
Article
Oncology
Sivesh K. Kamarajah, Wasfi Al-Rawashdeh, Alessandro Parente, Phil Atherton, George Salti, Fadi S. Dahdaleh, Derek Manas, Mohammed Abu Hilal, Steven A. White
Summary: This study found that adjuvant chemotherapy following resection for perihilar cholangiocarcinoma (hCCA) was associated with improved survival, even in margin-negative and node-negative disease.
Review
Oncology
Sinead Cremen, Michael E. Kelly, Tom K. Gallagher
Summary: Neoadjuvant therapy and surgical resection in patients with cholangiocarcinoma are associated with improved patient outcomes and longer median overall survival compared to upfront surgery, although heterogeneity between research papers limits the ability to further analyze the significance of these results.
FRONTIERS IN ONCOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Mingze Lu, Haoan Wu, Di Liu, Fei Wang, Yan Wang, Mengjun Wang, Qiannan Cui, He Zhang, Fengchao Zang, Ming Ma, Jun Ma, Fangfang Shi, Yu Zhang
Summary: This study designs a camouflaged nano-reactor that combines chemodynamic therapy and radiotherapy, effectively inhibiting malignant tumors. Experimental results demonstrate that the nano-reactor damages tumor cells through multiple mechanisms and addresses the limitations of chemodynamic therapy and radiotherapy.
Article
Oncology
Jennifer E. Lee, Carryn M. Anderson, Yelena Perkhounkova, Brittany M. Sleeuwenhoek, Rebecca R. Louison
Article
Otorhinolaryngology
Zachary Mayo, Steven N. Seyedin, Nadine Mallak, Sarah L. Mott, Yusuf Menda, Michael Graham, Carryn Anderson
ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY
(2019)
Editorial Material
Oncology
Danielle N. Margalit, Sana D. Karam, Melvin L. K. Chua, Carryn Anderson, Randall J. Kimple
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2020)
Article
Biology
Cameron M. Callaghan, Steven N. Seyedin, Imran H. Mohiuddin, Kelli L. Hawkes, Michael S. Petronek, Carryn M. Anderson, John M. Buatti, Mohammed M. Milhem, Varun Monga, Bryan G. Allen
RADIATION RESEARCH
(2020)
Article
Medicine, Research & Experimental
Christopher B. Sullivan, Zaid Al-Qurayshi, Carryn M. Anderson, Aaron T. Seaman, Nitin A. Pagedar
Summary: Older individuals, Medicare recipients, those living further from the surgical treatment facility, and lower-income individuals were more likely to receive postoperative radiation therapy (PORT) at a different facility. However, completion of PORT at a different facility was associated with inferior survival outcomes in head and neck cancer patients compared to completing it at the institution where surgery took place.
Editorial Material
Oncology
Sana D. Karam, Carryn M. Anderson, Daniel Ma, Melvin L. K. Chua, Randall J. Kimple
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Biology
Daniel C. Ma, Carryn M. Anderson, Samuel N. Rodman, Visarut Buranasudja, Michael L. McCormick, Andrew Davis, Elizabeth Loth, Kellie L. Bodeker, Logan Ahmann, Jessica R. Parkhurst, Wenqing Sun, Kayla R. Follmer, Andrean L. Simons, John M. Buatt, Douglas R. Spitz, Melissa A. Fath, Bryan G. Allen
Summary: Ketogenic diets may increase metabolic oxidative stress in head and neck cancer cells, enhancing sensitivity to radiation and platinum-based chemotherapy; however, a phase 1 clinical trial showed difficulties in maintaining diet compliance and associated toxicities.
RADIATION RESEARCH
(2021)
Article
Oncology
Varun Monga, Benjamin J. Miller, Munir Tanas, Sarag Boukhar, Bryan Allen, Carryn Anderson, Laura Stephens, Stacey Hartwig, Steven Varga, Jon Houtman, Lei Wang, Weizhou Zhang, Omar Jaber, Jon Thomason, David Kuehn, Maheen Rajput, Catherine Metz, K. D. Zamba, Sarah Mott, Chinemerem Abanonu, Sudershan Bhatia, Mohammed Milhem
Summary: The combination of preoperative intratumoral TVEC with concurrent EBRT for locally advanced STS is safe and well-tolerated, while potentially enhancing immune responses. This treatment did not significantly increase the rate of pathological necrosis, but Caspase-3 expression in TVEC-treated tissue samples may indicate a positive effect in sarcoma tumor tissue. Further studies on this biomarker are warranted.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Biochemistry & Molecular Biology
Kranti A. Mapuskar, Emily J. Steinbach, Amira Zaher, Dennis P. Riley, Robert A. Beardsley, Jeffery L. Keene, Jon T. Holmlund, Carryn M. Anderson, Diana Zepeda-Orozco, John M. Buatti, Douglas R. Spitz, Bryan G. Allen
Summary: Cisplatin is a widely used chemotherapy agent with potent anti-tumor activity, but it can cause renal injuries, leading to the need for intervention strategies to reduce kidney damage. In addition to DNA cross-linking, cisplatin affects mitochondrial metabolism, resulting in reactive oxygen species production and renal damage. Mitochondrial superoxide dismutase mimetics show potential in preventing platinum-associated nephrotoxicity.
Article
Oncology
Howard P. Safran, Kathryn Winter, David H. Ilson, Dennis Wigle, Thomas DiPetrillo, Michael G. Haddock, Theodore S. Hong, Lawrence P. Leichman, Lakshmi Rajdev, Murray Resnick, Lisa A. Kachnic, Samantha Seaward, Harvey Mamon, Dayssy Alexandra Diaz Pardo, Carryn M. Anderson, Xinglei Shen, Anand K. Sharma, Alan W. Katz, Jonathan Salo, Kara L. Leonard, Jennifer Moughan, Christopher H. Crane
Summary: The addition of trastuzumab to neoadjuvant chemoradiotherapy did not improve disease-free survival for patients with HER2-overexpressing esophageal cancer. Trastuzumab did not increase toxicities, suggesting the potential for future studies combining it with other agents targeting HER2 in esophageal cancer.
Article
Medicine, General & Internal
David A. P. Dunkerley, Daniel E. Hyer, Jeffrey E. Snyder, Joel J. St-Aubin, Carryn M. Anderson, Joseph M. Caster, Mark C. Smith, John M. Buatti, Sridhar Yaddanapudi
Summary: MRgART provides benefits for cancer patients through enhanced imaging technology during treatment, but also faces challenges. This paper presents an institution's experience in developing a MRgART program and provides considerations for treating patients at different anatomical sites.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Carryn M. Anderson, Christopher M. Lee, Deborah Saunders, Amarinthia E. Curtis, Neal E. Dunlap, Chaitali Nangia, Arielle S. Lee, Philip Kovoor, Voichita Bar-Ad, Abhinand V. Pedadda, Jon Holmlund, Matt Downs, Stephen T. Sonis
Summary: Avasopasem manganese does not significantly improve tumor control outcomes when used concurrently with cisplatin and radiation therapy for head and neck cancer. Additionally, it does not have a detectable effect on trismus or xerostomia.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Letter
Oncology
Carryn M. Anderson
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Ethan J. Ulrich, Yusuf Menda, Laura L. Boles Panto, Carryn M. Anderson, Brian J. Smith, John J. Sunderland, Michael M. Graham, John M. Buatti, Reinhard R. Beichel
Letter
Oncology
Melvin L. K. Chua, Daniel J. Ma, Carryn M. Anderson, Sana D. Karam, Danielle N. Margalit, Randall J. Kimple
ADVANCES IN RADIATION ONCOLOGY
(2020)
Review
Oncology
Albrecht Stenzinger, Arndt Vogel, Ulrich Lehmann, Angela Lamarca, Paul Hofman, Luigi Terracciano, Nicola Normanno
Summary: Cholangiocarcinomas are a heterogeneous group of tumors with distinct genomic alterations. Next-generation sequencing is a powerful tool for identifying gene variants and guiding personalized treatment for patients with cholangiocarcinomas. Understanding the use of NGS in molecular profiling is crucial for healthcare professionals to optimize treatment outcomes.
CANCER TREATMENT REVIEWS
(2024)
